Millennium Management LLC raised its position in shares of Amdocs Limited (NASDAQ:DOX) by 139.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 280,509 shares of the technology company’s stock after acquiring an additional 163,452 shares during the quarter. Millennium Management LLC owned about 0.20% of Amdocs worth $18,544,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Park Avenue Securities LLC boosted its holdings in Amdocs by 2.6% in the third quarter. Park Avenue Securities LLC now owns 6,197 shares of the technology company’s stock worth $410,000 after acquiring an additional 158 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Amdocs by 20.6% during the third quarter. Tower Research Capital LLC TRC now owns 1,000 shares of the technology company’s stock valued at $66,000 after buying an additional 171 shares during the last quarter. Robecosam AG increased its position in shares of Amdocs by 10.5% during the second quarter. Robecosam AG now owns 2,100 shares of the technology company’s stock worth $130,000 after acquiring an additional 200 shares in the last quarter. Huntington National Bank increased its position in shares of Amdocs by 7.6% during the third quarter. Huntington National Bank now owns 2,856 shares of the technology company’s stock worth $189,000 after acquiring an additional 202 shares in the last quarter. Finally, ETRADE Capital Management LLC increased its position in shares of Amdocs by 2.8% during the second quarter. ETRADE Capital Management LLC now owns 10,199 shares of the technology company’s stock worth $633,000 after acquiring an additional 279 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.
Shares of NASDAQ:DOX opened at $69.27 on Wednesday. The business has a fifty day moving average price of $67.14 and a two-hundred day moving average price of $64.36. The company has a market capitalization of $9.67 billion, a PE ratio of 17.02, a price-to-earnings-growth ratio of 1.92 and a beta of 0.40. Amdocs Limited has a 1 year low of $52.60 and a 1 year high of $69.85.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 24th. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.285 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $1.14 annualized dividend and a dividend yield of 1.65%. Amdocs’s payout ratio is currently 28.01%.
DOX has been the subject of several analyst reports. JPMorgan Chase & Co. lowered their price objective on Amdocs from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, November 13th. BidaskClub downgraded shares of Amdocs from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 15th. Finally, Stifel Nicolaus increased their price objective on shares of Amdocs from $70.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $71.33.
Amdocs Company Profile
Amdocs Limited, through its subsidiaries, provides software and services to the communications, pay TV, entertainment, and media industry service providers worldwide. The company offers amdocsONE a line of services designed for various stages of a service provider's lifecycle, including planning, delivery, implementation, and ongoing support, as well as consumer experience and monetization, media and digital, enterprise and connected society, service-driven network, and services and agile operation solutions.
See Also: Why Invest in Dividend Achievers?
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.